In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Athersys (ATHX), with a price target of $8. The company’s shares opened today at $1.57, close to its 52-week low of $1.29.
McCarthy observed:
“SanBio (SNBIF – NR), a cell therapy-focused company, recently missed the primary endpoint in its P2 stroke study. The trial should not be viewed as a read through to Athersys’ ongoing P3 MASTERS-2 or the Helios P3 TREASURE studies, in our view. Multiple reasons, sure, but the key reason is SanBio is targeting ‘stroke disability’ (long-term stroke effects) and Athersys is targeting initial stroke (within the first 36hrs)…yes, it’s stroke but it’s essentially two entirely different indications.”
According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.9% and a 31.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Sonoma Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Athersys has an analyst consensus of Moderate Buy, with a price target consensus of $8.
See today’s analyst top recommended stocks >>
Based on Athersys’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $9.74 million. In comparison, last year the company had a GAAP net loss of $13.1 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.
Read More on ATHX:
